{"gene":"PNPLA3","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2001,"finding":"Adiponutrin (PNPLA3) is a transmembrane protein that strictly localizes to membranes and is absent from the cytosol, as shown by Western blot and confocal imaging of epitope-tagged protein in 3T3-L1 adipocytes and COS cells. Its expression is exclusively in the adipose lineage and is tightly regulated by nutritional state (downregulated by fasting, dramatically induced by refeeding a high-carbohydrate diet).","method":"Western blot; confocal immunofluorescence imaging of epitope-tagged protein; mRNA differential display; Northern blot","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with epitope-tagged protein in two cell types, nutritional regulation confirmed in vivo, single lab","pmids":["11431482"],"is_preprint":false},{"year":2005,"finding":"Recombinant adiponutrin (PNPLA3) displays lipase activity in vitro that is dependent on the presence of the active-site serine; however, unlike ATGL/Desnutrin, overexpression of adiponutrin does not decrease intracellular triglyceride levels in cells, indicating it does not contribute to net lipolysis.","method":"In vitro lipase assay with recombinant proteins; active-site serine mutation; cell-based overexpression with intracellular triglyceride quantification","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro activity assay with mutagenesis and cell-based functional assay, single lab","pmids":["16150821"],"is_preprint":false},{"year":2006,"finding":"siRNA-mediated knockdown of adiponutrin (PNPLA3) in 3T3-L1 adipocytes had no effect on glycerol or NEFA release, indicating adiponutrin does not contribute to net adipocyte lipolysis. Adiponutrin is oppositely regulated by insulin compared to ATGL (insulin increases adiponutrin and decreases ATGL expression).","method":"siRNA knockdown; lipolysis assay (glycerol and NEFA measurement); insulin dose-response in 3T3-L1 adipocytes; in vivo streptozotocin diabetic mouse model","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean siRNA KD with specific readout, supported by in vivo regulation data, single lab","pmids":["16380488"],"is_preprint":false},{"year":2011,"finding":"Purified recombinant human PNPLA3 hydrolyzes triacylglycerol, diacylglycerol, and monoacylglycerol with preference for oleic acid as acyl moiety, and also catalyzes oleoyl-CoA thioesterase activity. The I148M substitution markedly decreases Vmax for glycerolipid substrates (loss of function) but has only modest effect on Km. PNPLA3 shows little to no hydrolytic activity against phospholipids, cholesteryl ester, or retinyl esters (by this assay), and neither WT nor I148M catalyzes de novo TAG synthesis.","method":"Purified recombinant protein; radiometric in vitro enzymatic assay; site-directed mutagenesis (catalytic serine; I148M); substrate specificity profiling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro with purified protein, mutagenesis, comprehensive substrate panel, replicated by multiple subsequent studies","pmids":["21878620"],"is_preprint":false},{"year":2010,"finding":"Germline knockout of Pnpla3 in mice does not cause fatty liver, elevated liver enzymes, or insulin resistance under normal chow, high-fat diet, high-sucrose diet, or in the ob/ob background, indicating loss of PNPLA3 function alone is insufficient to cause fatty liver in mice.","method":"Gene-targeted Pnpla3 knockout mouse; liver triglyceride measurement; plasma AST/ALT; glucose/insulin tolerance tests; multiple dietary challenges","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse with multiple dietary challenges and metabolic phenotyping, independently replicated (PMID 21068004)","pmids":["20648554","21068004"],"is_preprint":false},{"year":2013,"finding":"Purified recombinant PNPLA3 (expressed in Pichia pastoris) shows predominant triglyceride lipase activity and mild lysophosphatidic acid acyltransferase (LPAAT) activity; the I148M mutation results in loss of function of both activities.","method":"Pichia pastoris expression system; Ni-affinity protein purification; in vitro enzymatic assay with radiolabeled substrates; I148M mutant comparison","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro with purified protein from independent expression system, replicates and extends PMID 21878620","pmids":["24369119"],"is_preprint":false},{"year":2013,"finding":"PNPLA3 localizes to lipid droplets (LDs) via a process requiring an intact Brummer box domain. The NAFLD-linked I148M isoform leads to larger LDs upon overexpression, whereas decreased PNPLA3 levels produce smaller LDs. Co-expression of PNPLA3 with ABHD5/CGI-58 induces LD size reduction.","method":"Subcellular fractionation; immunofluorescence; live-cell imaging; overexpression and siRNA knockdown in fibroblast-like cells supplemented with lipids; domain deletion constructs","journal":"Biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization with domain mutants and functional readout (LD size), single lab","pmids":["23398201"],"is_preprint":false},{"year":2014,"finding":"Purified wild-type PNPLA3 hydrolyzes retinyl palmitate into retinol and palmitic acid in human hepatic stellate cells (HSCs). The I148M variant markedly reduces this retinyl-palmitate lipase activity. PNPLA3 is highly expressed in HSCs, its expression is regulated by retinol availability and insulin, and increased PNPLA3 expression reduces lipid droplet content and promotes extracellular retinol release.","method":"Purified recombinant protein enzymatic assay; primary human HSC culture; siRNA knockdown; overexpression; retinol measurement; PNPLA3 genotype correlation with circulating retinol-binding protein 4 in human cohort","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified protein, cell-based functional validation in primary human HSCs, and human cohort correlation, multiple orthogonal methods","pmids":["24670599"],"is_preprint":false},{"year":2014,"finding":"PNPLA3 mediates fatty acid-selective remodeling of triacylglycerols in hepatocytes. WT PNPLA3 accelerates turnover of oleic acid-labeled TAGs, while I148M impairs this activity and preferentially accumulates on lipid droplets compared to WT (which distributes more to ER/cytosol), consistent with impaired TAG remodeling causing lipid accumulation.","method":"13C-glycerol isotope labeling; D17-oleic acid pulse-chase; lipidomics; principal component analysis; subcellular fractionation; overexpression of WT and I148M in HuH7 cells","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal isotope labeling methods with subcellular localization, single lab","pmids":["24511104"],"is_preprint":false},{"year":2016,"finding":"In human hepatic stellate cells (LX-2), stable overexpression of WT PNPLA3 (but not I148M mutant) reduces secretion of MMP2, TIMP1, and TIMP2, and this effect is mediated through retinoid metabolism. TGF-β upregulates PNPLA3 expression in HSCs and is involved in TGF-β-induced lipid droplet reduction. Retinol release from primary human HSCs is lower in cells with I148M compared to WT.","method":"Stable lentiviral overexpression in LX-2 cells; primary human HSC culture; ELISA for MMP2/TIMP1/TIMP2; retinol measurement; siRNA knockdown; TGF-β treatment","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean overexpression with functional protein secretion readout and retinol assay, single lab","pmids":["27742777"],"is_preprint":false},{"year":2019,"finding":"PNPLA3(I148M) and the catalytically dead S47A mutant accumulate on hepatic lipid droplets when expressed in sucrose-fed mice and cause TG accumulation. Expression of a ubiquitylation-resistant form of PNPLA3 (which accumulates on LDs without loss of enzymatic activity) also causes fatty liver, demonstrating that LD accumulation of PNPLA3 itself—not loss of enzymatic activity—causes steatosis. Knockdown of PNPLA3 by shRNA or PROTAC-mediated degradation reduces liver TG in PNPLA3(148M)-overexpressing mice.","method":"AAV/adenoviral overexpression in mice; ubiquitylation-resistant PNPLA3 construct; shRNA knockdown; PROTAC degradation; liver TG measurement; LD immunostaining","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic constructs and orthogonal interventions (shRNA, PROTAC, engineered ubiquitylation-resistant variant) all pointing to the same conclusion in vivo","pmids":["31019090"],"is_preprint":false},{"year":2019,"finding":"PNPLA3 (WT and I148M) interacts directly with CGI-58 (ABHD5), the cofactor of ATGL, as shown by co-immunoprecipitation and in vitro pulldown with purified proteins. PNPLA3 requires CGI-58 for localization to hepatic LDs, and PNPLA3(148M)-induced steatosis requires CGI-58 presence. Co-expression of PNPLA3 with CGI-58 depletes LDs, consistent with PNPLA3 inhibiting ATGL by sequestering CGI-58.","method":"Co-immunoprecipitation in mouse liver and cultured cells; in vitro pulldown with purified proteins; liver-specific Cgi-58 KO mice; overexpression in HuH-7 cells; liver TG measurement","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal Co-IP, in vitro pulldown with purified proteins, genetic epistasis in Cgi-58 KO mice, multiple orthogonal methods","pmids":["30802989"],"is_preprint":false},{"year":2019,"finding":"In homozygous PNPLA3-I148M humans, VLDL-triglycerides are depleted of polyunsaturated fatty acids (PUFAs) under fasting and postprandial conditions. In PNPLA3-148M and PNPLA3-KO human cells, PUFA incorporation into TGs is increased at the expense of phosphatidylcholines, and PUFA-containing DAGs accumulate under lipolytic conditions compared to 148I cells. This establishes I148M as a loss-of-function allele that impairs hydrolysis/transacylation of PUFAs from DAGs to feed PC synthesis.","method":"Stable isotope tracer studies in humans; lipidomics in human cells with PNPLA3 genotype editing; VLDL-TG fatty acid composition in vivo; DAG accumulation assay","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — isotope tracing in vivo in humans plus isogenic cell models, multiple orthogonal methods, mechanistically definitive","pmids":["31434800"],"is_preprint":false},{"year":2019,"finding":"ASO-mediated silencing of Pnpla3 in Pnpla3-I148M knock-in mice reduces liver steatosis, inflammation score, and fibrosis stage on a NASH-inducing diet (but not in WT littermates for fibrosis). This establishes that the steatosis and fibrosis phenotype associated with PNPLA3-I148M is dependent on expression of the mutant protein.","method":"GalNAc3-conjugated ASO liver-targeted silencing; Pnpla3-I148M knock-in mouse model; liver histology scoring (steatosis, inflammation, fibrosis); Mcp1 and Timp2 mRNA measurement","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic precision (knock-in model vs WT controls), liver-targeted silencing, multiple histological endpoints, genotype-specific effect","pmids":["30772256"],"is_preprint":false},{"year":2019,"finding":"PNPLA3 I148M mediates NF-κB-driven inflammation in hepatocytes. NF-κB (p65/p50) binds a site in the PNPLA3 promoter to drive transcription; PNPLA3 silencing blocks NF-κB- or palmitic acid-induced TNF-α upregulation; mutant (but not WT) PNPLA3 overexpression activates the ER stress IRE-1α/JNK/c-Jun inflammatory pathway independently of NF-κB.","method":"Luciferase reporter assay; EMSA; ChIP-qPCR; siRNA knockdown; stable lentiviral overexpression; supershift analysis confirming p65/p50 complex","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (luciferase, EMSA, ChIP, siRNA), single lab","pmids":["31793207"],"is_preprint":false},{"year":2019,"finding":"In primary I148M HSCs, LXRα protein is elevated but LXR target gene expression is reduced, LXR transcriptional activity is decreased, and cholesterol efflux is diminished while free cholesterol accumulates. The synthetic LXR agonist T0901317 restores LXR functionality and reduces pro-fibrogenic gene expression in I148M HSCs.","method":"Primary human HSC culture stratified by PNPLA3 genotype; LXR luciferase reporter assay; qRT-PCR of LXR targets; cholesterol assays; LXR agonist treatment","journal":"Hepatology communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genotype-stratified primary human HSCs with functional assays, single lab, no independent replication","pmids":["31497741"],"is_preprint":false},{"year":2020,"finding":"PNPLA3 is highly abundant at the protein level in human adipose tissue (3-fold higher per tissue protein than liver). PNPLA3-I148M locally remodels adipose tissue TGs to become enriched in polyunsaturated species (PUFA-TGs increased in AT of variant carriers) without altering the rate of lipolysis or serum NEFA composition.","method":"PNPLA3 mRNA and protein quantification in paired liver and adipose tissue biopsies; AT lipidomics; [2H5]glycerol lipolysis tracer; genotype-stratified comparison","journal":"Liver international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein quantification in human tissue biopsies with lipidomics, single lab","pmids":["32386450"],"is_preprint":false},{"year":2022,"finding":"The I148M variant drives enhanced NAFLD phenotype development through elevated IL-6/STAT3 and NF-κB activity in an isogenic hPSC-derived multicellular liver culture (hepatocytes, stellate cells, macrophages). Dampening IL-6/STAT3 activity alleviated I148M-mediated NAFLD phenotypes; boosting IL-6/STAT3 in WT cultures enhanced NAFLD, establishing a causal link.","method":"Isogenic hPSC-derived multicellular liver organoid system; CRISPR-Cas9 isogenic editing of rs738049; IL-6/STAT3 pathway inhibition/activation; transcriptomic analysis corroborated with human liver biopsy data","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isogenic CRISPR model with rescue experiment and pathway manipulation, single lab, corroborated by human transcriptomics","pmids":["36049612"],"is_preprint":false},{"year":2023,"finding":"Estrogen receptor-α (ER-α) binds a functional enhancer element within the PNPLA3 locus to upregulate PNPLA3 expression. CRISPR-Cas9 deletion of this ER-α-binding site reduces PNPLA3-I148M upregulation and attenuates lipid droplet accumulation and fibrogenesis in 3D multilineage spheroids with stellate cells. Hepatic PNPLA3 expression is higher in women than men in obesity and correlates with estrogen levels in mice.","method":"Chromatin immunoprecipitation (ChIP); luciferase reporter assay; CRISPR-Cas9 genome editing of ER-α binding site; 3D multilineage liver spheroids; hepatocyte and liver organoid treatment with ER-α agonists","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP, luciferase, CRISPR deletion, and functional validation in 3D organoids, multiple orthogonal methods in single rigorous study","pmids":["37749332"],"is_preprint":false},{"year":2023,"finding":"Homozygous PNPLA3 I148M carriers have higher plasma β-hydroxybutyrate, lower hepatic de novo lipogenesis (DNL), and increased channeling of fatty acids toward ketogenesis associated with hepatic mitochondrial redox changes and decreased mitochondrial citrate synthase flux, demonstrating that the variant causes hepatic mitochondrial dysfunction.","method":"Stable isotope tracer studies (deuterium water for DNL; 13C acetate for ketogenesis); hepatic mitochondrial redox measurements; ketogenic diet challenge; genotype-stratified human study","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — state-of-the-art stable isotope techniques in humans under multiple physiological conditions, genotype-stratified, multiple orthogonal metabolic measurements","pmids":["37909034"],"is_preprint":false},{"year":2024,"finding":"BFAR (bifunctional apoptosis regulator), a membrane-bound E3 ubiquitin ligase, promotes ubiquitylation and proteasomal/autophagic degradation of PNPLA3. BFAR and PNPLA3 co-immunoprecipitate when co-expressed; BFAR promotes PNPLA3 ubiquitylation in a reconstitution assay with purified proteins; BFAR knockdown increases PNPLA3 levels and Bfar KO mice show increased PNPLA3 protein on hepatic LDs without increased mRNA.","method":"siRNA screen of ubiquitin proteasome components; co-immunoprecipitation; in vitro ubiquitylation reconstitution assay with purified proteins; Bfar KO mouse; PNPLA3 protein/mRNA quantification","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro reconstitution of ubiquitylation, co-IP, and genetic validation in KO mouse, multiple orthogonal methods in single study","pmids":["38294943"],"is_preprint":false},{"year":2024,"finding":"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by accumulating on lipid droplets and sequestering ABHD5 (CGI-58) away from ATGL, thereby inhibiting ATGL-mediated TG hydrolysis. ABHD5 interacts preferentially with PNPLA3 over ATGL in hepatocytes. PNPLA3(WT and 148M) are both activated by ABHD5 in vitro. The steatotic effect requires ATGL expression and LD localization of PNPLA3. Overexpression of ABHD5 in Pnpla3(M/M) mice reverses hepatic steatosis.","method":"NanoBiT complementation assay for protein-protein interactions; immunocytochemistry; in vitro TG hydrolysis assay with purified recombinant proteins ± ABHD5; adenoviral/AAV overexpression in liver-specific Atgl-/- mice; ABHD5 overexpression in Pnpla3M/M mice; liver TG measurement","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro reconstitution, NanoBiT interaction assay, multiple genetic mouse models, epistasis experiment (ABHD5 rescue), mechanistically definitive","pmids":["39550037"],"is_preprint":false},{"year":2024,"finding":"At endogenous expression levels, PNPLA3 and PNPLA3-I148M are not ER-resident transmembrane proteins but are enriched in lipid droplet, Golgi, and endosomal fractions. PNPLA3-I148M induces morphological changes in the Golgi apparatus including increased lipid droplet-Golgi contact sites, observed both in isogenic hepatoma cells and primary human I148M-expressing hepatocytes.","method":"Isogenic CRISPR-engineered human hepatoma cell lines expressing PNPLA3 at endogenous levels; subcellular fractionation; immunofluorescence; electron microscopy; phosphoinositide binding assay with purified protein; proteomics; primary human hepatocytes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — endogenous expression isogenic system, multiple fractionation/imaging approaches, validated in primary patient hepatocytes, multiple orthogonal methods","pmids":["38657050"],"is_preprint":false},{"year":2024,"finding":"TM6SF2 E167K variant increases physical interaction between TM6SF2 and PNPLA3, and impairs PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to phosphatidylcholine (PC), as shown in Tm6sf2-E167K knock-in mice on high-fat diet using lipidomics and TLC-based newly synthesized lipid measurement.","method":"Tm6sf2-E167K knock-in mouse; high-fat diet challenge; lipidomics; thin-layer chromatography for newly synthesized TG and PC; co-immunoprecipitation (TM6SF2–PNPLA3 interaction)","journal":"Clinical and molecular hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KI mouse model with lipidomics and Co-IP, single lab, mechanism of PNPLA3 transacylation activity implicated","pmids":["39054606"],"is_preprint":false},{"year":2010,"finding":"The PNPLA3/adiponutrin promoter is regulated by glucose and insulin: glucose (25 mM) induces promoter activity 4.7-fold in HepG2 cells and 2-fold in CHO cells in a glucose metabolism-dependent manner; insulin has an additive effect in cells expressing the insulin receptor. USF2 transcription factor co-transfection further potentiates insulin-driven promoter activity.","method":"Luciferase reporter assay; promoter cloning; CHO-IR cell system; USF2 co-transfection; non-metabolizable glucose analog control","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — luciferase reporter with mutagenesis controls and non-metabolizable analog, single lab","pmids":["21036152"],"is_preprint":false},{"year":2020,"finding":"In PNPLA3-I148M HSCs, expression and activation of the endogenous TGF-β inhibitor NR4A1 are decreased; NR4A1 regulation by TGF-β/cytosporone B was linked to Akt signaling in WT HSCs but Erk signaling in I148M HSCs. PNPLA3-I148M HSCs show impaired mitochondrial function (respiratory chain complex IV insufficiency), lower antioxidant capacity, increased ROS secretion, and increased TGF-β signaling.","method":"RNA sequencing of primary human HSCs and liver biopsies; 3D extracellular matrix scaffold culture; mitochondrial respirometry; ROS measurement; TGF-β and cytosporone B treatment; signaling pathway inhibitors","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptomics plus 3D model validation with functional assays, single lab","pmids":["38365182"],"is_preprint":false},{"year":2020,"finding":"PNPLA3-I148M in HSCs causes mitochondrial dysfunction through accumulation of free cholesterol (by decreasing ABCG1-mediated cholesterol efflux), leading to attenuated ATP production, decreased mitochondrial membrane potential, elevated ROS, and structural mitochondrial damage, thereby promoting HSC activation and fibrosis.","method":"Immunofluorescence; ELISA; real-time PCR; Western blot; electron microscopy; Seahorse XFe96 mitochondrial respirometry; cholesterol efflux assay in LX-2 cells overexpressing I148M vs WT","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays in cell line, single lab, mechanistic pathway identified","pmids":["37298640"],"is_preprint":false}],"current_model":"PNPLA3 is a lipid droplet-associated serine hydrolase that, in hepatocytes, hydrolyzes triglycerides, diacylglycerols, and performs transacylation of polyunsaturated fatty acids from DAG to phosphatidylcholines, and in hepatic stellate cells also hydrolyzes retinyl palmitate to release retinol; the common I148M variant causes loss of enzymatic activity but, more critically, resists ubiquitin-mediated proteasomal/autophagic turnover (via the E3 ligase BFAR) and accumulates on lipid droplets where it sequesters the ATGL cofactor ABHD5 (CGI-58), thereby acting as a gain-of-function inhibitor of ATGL-mediated triglyceride hydrolysis to drive hepatic steatosis; in hepatic stellate cells the I148M variant additionally impairs retinol release, disrupts LXR-mediated cholesterol homeostasis, activates Yap/Hedgehog and TGF-β/NF-κB/IL-6-STAT3 pro-fibrogenic signaling, and causes mitochondrial dysfunction, collectively explaining its role in promoting the full spectrum of fatty liver disease from steatosis to fibrosis and hepatocellular carcinoma."},"narrative":{"mechanistic_narrative":"PNPLA3 is a lipid droplet-associated serine hydrolase that governs the remodeling of stored neutral lipids in hepatocytes and hepatic stellate cells, and its common I148M variant is a principal driver of fatty liver disease [PMID:21878620, PMID:39550037]. The purified enzyme hydrolyzes triacylglycerol, diacylglycerol, and monoacylglycerol with preference for oleate and additionally catalyzes acyltransferase reactions, activities that depend on its catalytic serine and are largely lost by the I148M substitution [PMID:21878620, PMID:24369119]. Mechanistically, PNPLA3 mediates fatty acid-selective remodeling of triglycerides, transferring polyunsaturated fatty acids from triglyceride/diacylglycerol pools toward phosphatidylcholine synthesis; I148M impairs this transacylation, depleting VLDL-triglycerides of PUFAs and causing accumulation of PUFA-containing diacylglycerols [PMID:24511104, PMID:31434800]. In hepatic stellate cells PNPLA3 instead hydrolyzes retinyl palmitate to release retinol, an activity also lost in the I148M protein [PMID:24670599]. The decisive lesion in disease is not loss of catalysis but accumulation of the protein on lipid droplets: a ubiquitylation-resistant PNPLA3 that retains enzymatic activity still causes steatosis, establishing droplet accumulation itself as the steatotic driver [PMID:31019090]. This accumulation reflects escape from turnover normally imposed by the membrane-bound E3 ubiquitin ligase BFAR, which ubiquitylates PNPLA3 to direct its proteasomal/autophagic degradation [PMID:38294943]. Accumulated PNPLA3 acts as a gain-of-function inhibitor of ATGL-mediated lipolysis by binding and sequestering the ATGL cofactor ABHD5/CGI-58; CGI-58 is required for PNPLA3 localization to droplets and for I148M-driven steatosis, and ABHD5 overexpression reverses steatosis in I148M mice [PMID:30802989, PMID:39550037]. Beyond steatosis, the I148M variant drives the progression of liver disease through stellate-cell mitochondrial dysfunction, disrupted LXR-dependent cholesterol homeostasis, and activation of NF-κB and IL-6/STAT3 pro-inflammatory and pro-fibrogenic signaling [PMID:31497741, PMID:36049612, PMID:37298640]. PNPLA3 expression is transcriptionally controlled by nutritional and hormonal cues, including glucose/insulin and estrogen receptor-α acting at a hepatic enhancer [PMID:16150821, PMID:21036152, PMID:37749332].","teleology":[{"year":2001,"claim":"Established PNPLA3 as a nutritionally regulated, membrane-associated protein, framing it as a metabolic effector rather than a cytosolic enzyme.","evidence":"Western blot and confocal imaging of epitope-tagged protein in adipocyte/COS cells with nutritional regulation in vivo","pmids":["11431482"],"confidence":"Medium","gaps":["Did not define enzymatic activity or substrate","Adipose-restricted view later revised by hepatic and stellate-cell findings"]},{"year":2005,"claim":"Showed PNPLA3 possesses intrinsic serine-dependent lipase activity yet does not drive net cellular lipolysis, distinguishing it from ATGL.","evidence":"In vitro lipase assay with recombinant protein, active-site serine mutant, and cell-based triglyceride quantification","pmids":["16150821"],"confidence":"Medium","gaps":["Did not resolve physiological substrate","Disconnect between in vitro activity and cellular phenotype unexplained"]},{"year":2006,"claim":"Confirmed PNPLA3 is dispensable for adipocyte lipolysis and is regulated oppositely to ATGL by insulin, sharpening its functional separation from canonical lipases.","evidence":"siRNA knockdown with glycerol/NEFA lipolysis readout and insulin dose-response in 3T3-L1 adipocytes","pmids":["16380488"],"confidence":"Medium","gaps":["No insight into hepatic role","Substrate and direction of acyl chemistry unresolved"]},{"year":2010,"claim":"Demonstrated that loss of PNPLA3 function alone does not cause fatty liver, redirecting the field away from a simple loss-of-function model.","evidence":"Gene-targeted knockout mice across multiple dietary and ob/ob challenges with liver TG and metabolic phenotyping","pmids":["20648554","21068004"],"confidence":"High","gaps":["Did not explain how the human I148M variant causes disease","Implied a gain-of-function or species-specific mechanism not yet defined"]},{"year":2010,"claim":"Defined transcriptional control of PNPLA3 by glucose and insulin, linking its expression to nutritional state at the promoter level.","evidence":"Luciferase promoter reporter assays in HepG2/CHO-IR cells with USF2 co-transfection and non-metabolizable glucose control","pmids":["21036152"],"confidence":"Medium","gaps":["Single transcription factor (USF2) tested","Did not connect expression level to disease phenotype"]},{"year":2011,"claim":"Reconstituted PNPLA3 as a glycerolipid hydrolase with oleate preference and showed I148M reduces Vmax, providing the first biochemical definition of the disease variant's enzymatic defect.","evidence":"Purified recombinant protein, radiometric assays, catalytic-serine and I148M mutagenesis, substrate panel","pmids":["21878620"],"confidence":"High","gaps":["Loss of activity insufficient given KO mouse data","No phospholipid or retinyl ester activity detected in this assay"]},{"year":2013,"claim":"Independently confirmed triglyceride lipase activity (plus mild LPAAT activity) and the I148M loss-of-function, while localizing PNPLA3 to lipid droplets via the Brummer-box domain with droplet-size phenotypes.","evidence":"Pichia-expressed purified protein assays; subcellular fractionation, imaging, domain-deletion and ABHD5 co-expression in cells","pmids":["24369119","23398201"],"confidence":"High","gaps":["Mechanism linking droplet localization to enlargement unresolved","Role of ABHD5 interaction not yet characterized"]},{"year":2014,"claim":"Revealed two tissue-specific catalytic roles: fatty acid-selective TAG remodeling in hepatocytes and retinyl-palmitate hydrolysis in stellate cells, both impaired by I148M.","evidence":"Isotope pulse-chase/lipidomics in HuH7 cells; purified-protein retinyl ester assay, primary human HSCs, and human cohort RBP4 correlation","pmids":["24511104","24670599"],"confidence":"High","gaps":["Did not establish whether remodeling defect alone causes steatosis","Connection between hepatocyte and stellate-cell roles unclear"]},{"year":2016,"claim":"Linked PNPLA3 retinoid metabolism to fibrogenic output, showing WT but not I148M suppresses MMP2/TIMP secretion and that TGF-β induces PNPLA3 in stellate cells.","evidence":"Stable overexpression in LX-2 cells and primary HSCs with ELISA, retinol measurement, siRNA, and TGF-β treatment","pmids":["27742777"],"confidence":"Medium","gaps":["Causal chain from retinoid defect to fibrosis incomplete","Single cell-line/primary-cell system"]},{"year":2019,"claim":"Overturned the loss-of-function paradigm by showing droplet accumulation of PNPLA3 itself, independent of catalytic activity, causes steatosis, and that degrading PNPLA3 reverses it.","evidence":"AAV/adenoviral overexpression in mice, ubiquitylation-resistant and catalytically dead constructs, shRNA and PROTAC degradation, liver TG and LD imaging","pmids":["31019090"],"confidence":"High","gaps":["Molecular consequence of droplet accumulation not yet defined","Identity of the turnover machinery unknown at this point"]},{"year":2019,"claim":"Identified the gain-of-function mechanism: PNPLA3 binds CGI-58/ABHD5, requires it for droplet localization, and sequesters it from ATGL to inhibit lipolysis.","evidence":"Reciprocal Co-IP, in vitro pulldown with purified proteins, liver-specific Cgi-58 KO epistasis, and HuH-7 overexpression","pmids":["30802989"],"confidence":"High","gaps":["Stoichiometry and preferential binding versus ATGL not yet quantified","How accumulation is achieved physiologically unresolved"]},{"year":2019,"claim":"Pinpointed the in vivo human metabolic defect of I148M as impaired transfer of PUFAs from DAG/TG toward phosphatidylcholine, depleting VLDL-TG of PUFAs.","evidence":"Stable isotope tracers in homozygous I148M humans plus isogenic genotype-edited human cells with lipidomics","pmids":["31434800"],"confidence":"High","gaps":["Relationship between transacylation defect and droplet accumulation not integrated","Tissue-specific contribution of liver vs adipose unclear"]},{"year":2019,"claim":"Demonstrated genotype-dependent reversibility, with ASO silencing of mutant PNPLA3 reducing steatosis, inflammation, and fibrosis in I148M knock-in mice.","evidence":"GalNAc3-ASO liver-targeted silencing in Pnpla3-I148M knock-in mice with histological scoring","pmids":["30772256"],"confidence":"High","gaps":["Fibrosis effect not seen in WT controls","Downstream signaling mediators not defined here"]},{"year":2019,"claim":"Connected PNPLA3-I148M to hepatocyte inflammation via NF-κB (which also drives PNPLA3 transcription) and an ER-stress IRE-1α/JNK/c-Jun axis.","evidence":"Luciferase, EMSA/supershift, ChIP-qPCR, siRNA, and stable overexpression in hepatocyte models","pmids":["31793207"],"confidence":"Medium","gaps":["Single lab","Causal contribution to in vivo inflammation not isolated"]},{"year":2019,"claim":"Showed I148M disrupts LXR-dependent cholesterol homeostasis in stellate cells and that an LXR agonist restores function and reduces fibrogenic gene expression.","evidence":"Genotype-stratified primary human HSCs with LXR luciferase reporter, target qPCR, cholesterol assays, and T0901317 treatment","pmids":["31497741"],"confidence":"Medium","gaps":["No independent replication","Mechanistic link from lipase defect to LXR dysfunction not defined"]},{"year":2020,"claim":"Quantified PNPLA3 as highly abundant in human adipose tissue and showed I148M remodels adipose TGs toward PUFA enrichment without altering lipolysis.","evidence":"Paired liver/adipose protein quantification, AT lipidomics, and glycerol tracer in genotype-stratified humans","pmids":["32386450"],"confidence":"Medium","gaps":["Functional consequence of adipose remodeling for systemic disease unclear","Single lab"]},{"year":2020,"claim":"Defined stellate-cell mitochondrial dysfunction as a fibrogenic consequence of I148M, driven by free-cholesterol accumulation and altered TGF-β/NR4A1 signaling with elevated ROS.","evidence":"RNA-seq, 3D ECM and LX-2 culture, Seahorse respirometry, cholesterol efflux assays, signaling inhibitors","pmids":["38365182","37298640"],"confidence":"Medium","gaps":["Single-lab cell models","Direct link from enzyme defect to mitochondrial damage not fully reconstituted"]},{"year":2022,"claim":"Established IL-6/STAT3 as a causal pro-NAFLD pathway downstream of I148M using an isogenic multicellular human liver system with bidirectional manipulation.","evidence":"hPSC-derived multicellular liver organoids, CRISPR isogenic rs738049 editing, IL-6/STAT3 inhibition and activation, human transcriptomic corroboration","pmids":["36049612"],"confidence":"Medium","gaps":["Single model system","Upstream trigger connecting PNPLA3 to IL-6/STAT3 not defined"]},{"year":2023,"claim":"Identified estrogen receptor-α binding at a hepatic enhancer as a sex-dependent transcriptional driver of PNPLA3, providing a mechanism for sex differences in expression and fibrogenesis.","evidence":"ChIP, luciferase, CRISPR deletion of the ER-α site, and 3D multilineage spheroid functional validation","pmids":["37749332"],"confidence":"High","gaps":["Quantitative contribution to clinical sex differences not established","Interaction with nutritional regulators not integrated"]},{"year":2023,"claim":"Demonstrated I148M causes hepatic mitochondrial dysfunction in humans, shifting fatty acids toward ketogenesis and reducing de novo lipogenesis and citrate synthase flux.","evidence":"Deuterium water and 13C-acetate tracers with mitochondrial redox measurements in genotype-stratified humans under ketogenic challenge","pmids":["37909034"],"confidence":"High","gaps":["Causal link from droplet accumulation to mitochondrial change not mechanistically traced","Hepatocyte vs stellate-cell contributions not separated"]},{"year":2024,"claim":"Identified BFAR as the E3 ligase that ubiquitylates PNPLA3 for degradation, explaining how mutant protein evades turnover to accumulate on droplets.","evidence":"Ubiquitin-proteasome siRNA screen, Co-IP, in vitro ubiquitylation reconstitution with purified proteins, and Bfar KO mice","pmids":["38294943"],"confidence":"High","gaps":["Whether I148M specifically resists BFAR-mediated ubiquitylation not fully quantified","Relative roles of proteasomal vs autophagic disposal unresolved"]},{"year":2024,"claim":"Provided the definitive gain-of-function model: PNPLA3 preferentially binds ABHD5 over ATGL, requires ATGL and droplet localization for steatosis, and ABHD5 overexpression reverses the phenotype.","evidence":"NanoBiT interaction assays, in vitro TG hydrolysis with purified proteins ± ABHD5, liver-specific Atgl-/- mice, and ABHD5 rescue in Pnpla3 M/M mice","pmids":["39550037"],"confidence":"High","gaps":["Structural basis of ABHD5 preference unresolved","Integration with transacylation defect mechanism not fully reconciled"]},{"year":2024,"claim":"Revised the subcellular localization model, showing endogenous PNPLA3 is enriched in lipid droplet, Golgi, and endosomal fractions rather than the ER, and that I148M alters Golgi morphology and LD-Golgi contacts.","evidence":"Isogenic endogenous-expression hepatoma lines, fractionation, immunofluorescence, EM, phosphoinositide binding, proteomics, and primary patient hepatocytes","pmids":["38657050"],"confidence":"High","gaps":["Functional role of Golgi/endosomal pools unclear","Significance of LD-Golgi contact sites for disease undefined"]},{"year":2024,"claim":"Linked PNPLA3 to TM6SF2 genetically, showing the TM6SF2-E167K variant enhances TM6SF2-PNPLA3 interaction and impairs PNPLA3-mediated PUFA transfer from TG to PC.","evidence":"Tm6sf2-E167K knock-in mice on high-fat diet, lipidomics, TLC of newly synthesized lipids, and Co-IP","pmids":["39054606"],"confidence":"Medium","gaps":["Single lab","Whether TM6SF2 modulates PNPLA3 in humans not established"]},{"year":null,"claim":"How the transacylation/PUFA-remodeling defect, droplet accumulation with ABHD5 sequestration, and downstream mitochondrial and pro-fibrogenic signaling are causally integrated into a single quantitative mechanism remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of PNPLA3 or PNPLA3-ABHD5 complex in the corpus","Causal order linking droplet accumulation to mitochondrial and signaling phenotypes not established","Therapeutic degradation strategies not validated clinically"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3,5,7]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[5,12,23]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[11,21]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[22]}],"localization":[{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[6,8,10,22]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[22]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,8,12,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,13,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,17,25]}],"complexes":[],"partners":["ABHD5","ATGL","BFAR","TM6SF2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NST1","full_name":"1-acylglycerol-3-phosphate O-acyltransferase PNPLA3","aliases":["Acylglycerol transacylase","Adiponutrin","ADPN","Calcium-independent phospholipase A2-epsilon","iPLA2-epsilon","Lysophosphatidic acid acyltransferase","Patatin-like phospholipase domain-containing protein 3"],"length_aa":481,"mass_kda":52.9,"function":"Specifically catalyzes coenzyme A (CoA)-dependent acylation of 1-acyl-sn-glycerol 3-phosphate (2-lysophosphatidic acid/LPA) to generate phosphatidic acid (PA), an important metabolic intermediate and precursor for both triglycerides and glycerophospholipids. Does not esterify other lysophospholipids. Acyl donors are long chain (at least C16) fatty acyl-CoAs: arachidonoyl-CoA, linoleoyl-CoA, oleoyl-CoA and at a lesser extent palmitoyl-CoA (PubMed:22560221). Additionally possesses low triacylglycerol lipase and CoA-independent acylglycerol transacylase activities and thus may play a role in acyl-chain remodeling of triglycerides (PubMed:15364929, PubMed:20034933, PubMed:22560221). In vitro may express hydrolytic activity against glycerolipids triacylglycerol, diacylglycerol and monoacylglycerol, with a strong preference for oleic acid as the acyl moiety (PubMed:21878620). However, the triacylglycerol hydrolase activity is controversial and may be very low (PubMed:22560221). Possesses phospholipase A2 activity (PubMed:15364929)","subcellular_location":"Membrane; Lipid droplet","url":"https://www.uniprot.org/uniprotkb/Q9NST1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PNPLA3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PNPLA3","total_profiled":1310},"omim":[{"mim_id":"620116","title":"FATTY LIVER DISEASE, PROTECTION FROM; FLDP","url":"https://www.omim.org/entry/620116"},{"mim_id":"613282","title":"FATTY LIVER DISEASE, SUSCEPTIBILITY TO, 1; FLD1","url":"https://www.omim.org/entry/613282"},{"mim_id":"612364","title":"ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 2","url":"https://www.omim.org/entry/612364"},{"mim_id":"612127","title":"17-@BETA-HYDROXYSTEROID DEHYDROGENASE XIII; HSD17B13","url":"https://www.omim.org/entry/612127"},{"mim_id":"609567","title":"PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3; PNPLA3","url":"https://www.omim.org/entry/609567"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoli","reliability":"Approved"},{"location":"Mitochondria","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":29.0}],"url":"https://www.proteinatlas.org/search/PNPLA3"},"hgnc":{"alias_symbol":["dJ796I17.1","FLJ22012","adiponutrin","iPLA2epsilon"],"prev_symbol":["C22orf20","ADPN"]},"alphafold":{"accession":"Q9NST1","domains":[{"cath_id":"3.40.1090","chopping":"10-257_309-336","consensus_level":"high","plddt":86.0197,"start":10,"end":336},{"cath_id":"-","chopping":"344-398","consensus_level":"high","plddt":80.1878,"start":344,"end":398}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NST1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NST1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NST1-F1-predicted_aligned_error_v6.png","plddt_mean":71.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PNPLA3","jax_strain_url":"https://www.jax.org/strain/search?query=PNPLA3"},"sequence":{"accession":"Q9NST1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NST1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NST1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NST1"}},"corpus_meta":[{"pmid":"20373368","id":"PMC_20373368","title":"Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.","date":"2010","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20373368","citation_count":539,"is_preprint":false},{"pmid":"19738004","id":"PMC_19738004","title":"A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.","date":"2009","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19738004","citation_count":308,"is_preprint":false},{"pmid":"24670599","id":"PMC_24670599","title":"PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24670599","citation_count":298,"is_preprint":false},{"pmid":"16380488","id":"PMC_16380488","title":"Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/16380488","citation_count":290,"is_preprint":false},{"pmid":"21878620","id":"PMC_21878620","title":"Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21878620","citation_count":259,"is_preprint":false},{"pmid":"19224197","id":"PMC_19224197","title":"A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.","date":"2009","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/19224197","citation_count":250,"is_preprint":false},{"pmid":"31019090","id":"PMC_31019090","title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31019090","citation_count":248,"is_preprint":false},{"pmid":"16150821","id":"PMC_16150821","title":"Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members.","date":"2005","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16150821","citation_count":247,"is_preprint":false},{"pmid":"27038645","id":"PMC_27038645","title":"PNPLA3 gene in liver diseases.","date":"2016","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/27038645","citation_count":221,"is_preprint":false},{"pmid":"20648554","id":"PMC_20648554","title":"Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease.","date":"2010","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20648554","citation_count":214,"is_preprint":false},{"pmid":"11431482","id":"PMC_11431482","title":"Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11431482","citation_count":209,"is_preprint":false},{"pmid":"24222941","id":"PMC_24222941","title":"PNPLA3 I148M polymorphism and progressive liver disease.","date":"2013","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/24222941","citation_count":208,"is_preprint":false},{"pmid":"21068004","id":"PMC_21068004","title":"Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/21068004","citation_count":204,"is_preprint":false},{"pmid":"24114809","id":"PMC_24114809","title":"Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data.","date":"2014","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/24114809","citation_count":196,"is_preprint":false},{"pmid":"30802989","id":"PMC_30802989","title":"PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice.","date":"2019","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/30802989","citation_count":181,"is_preprint":false},{"pmid":"30772256","id":"PMC_30772256","title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.","date":"2019","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30772256","citation_count":178,"is_preprint":false},{"pmid":"24369119","id":"PMC_24369119","title":"Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24369119","citation_count":160,"is_preprint":false},{"pmid":"31434800","id":"PMC_31434800","title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31434800","citation_count":136,"is_preprint":false},{"pmid":"21525193","id":"PMC_21525193","title":"Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans.","date":"2011","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/21525193","citation_count":130,"is_preprint":false},{"pmid":"25040896","id":"PMC_25040896","title":"PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease.","date":"2015","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25040896","citation_count":129,"is_preprint":false},{"pmid":"25964223","id":"PMC_25964223","title":"PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease.","date":"2015","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25964223","citation_count":127,"is_preprint":false},{"pmid":"21334404","id":"PMC_21334404","title":"Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease.","date":"2011","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/21334404","citation_count":125,"is_preprint":false},{"pmid":"36049612","id":"PMC_36049612","title":"IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.","date":"2022","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36049612","citation_count":114,"is_preprint":false},{"pmid":"27742777","id":"PMC_27742777","title":"PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27742777","citation_count":109,"is_preprint":false},{"pmid":"25791171","id":"PMC_25791171","title":"Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25791171","citation_count":108,"is_preprint":false},{"pmid":"37749332","id":"PMC_37749332","title":"Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.","date":"2023","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37749332","citation_count":106,"is_preprint":false},{"pmid":"24511104","id":"PMC_24511104","title":"PNPLA3 mediates hepatocyte triacylglycerol remodeling.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/24511104","citation_count":97,"is_preprint":false},{"pmid":"29935383","id":"PMC_29935383","title":"The role of PNPLA3 in health and disease.","date":"2018","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/29935383","citation_count":92,"is_preprint":false},{"pmid":"34823063","id":"PMC_34823063","title":"TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.","date":"2021","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34823063","citation_count":89,"is_preprint":false},{"pmid":"23398201","id":"PMC_23398201","title":"PNPLA3/adiponutrin functions in lipid droplet formation.","date":"2013","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/23398201","citation_count":80,"is_preprint":false},{"pmid":"15181042","id":"PMC_15181042","title":"Adiponutrin: A new gene regulated by energy balance in human adipose tissue.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15181042","citation_count":75,"is_preprint":false},{"pmid":"30762732","id":"PMC_30762732","title":"Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30762732","citation_count":73,"is_preprint":false},{"pmid":"24222094","id":"PMC_24222094","title":"PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.","date":"2013","source":"Seminars in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/24222094","citation_count":72,"is_preprint":false},{"pmid":"21168459","id":"PMC_21168459","title":"Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease.","date":"2010","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/21168459","citation_count":68,"is_preprint":false},{"pmid":"18728122","id":"PMC_18728122","title":"Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity.","date":"2008","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18728122","citation_count":66,"is_preprint":false},{"pmid":"23800943","id":"PMC_23800943","title":"Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.","date":"2013","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23800943","citation_count":66,"is_preprint":false},{"pmid":"37909034","id":"PMC_37909034","title":"The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans.","date":"2023","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37909034","citation_count":65,"is_preprint":false},{"pmid":"34904923","id":"PMC_34904923","title":"PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.","date":"2021","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/34904923","citation_count":64,"is_preprint":false},{"pmid":"36190732","id":"PMC_36190732","title":"Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality.","date":"2022","source":"JAMA network open","url":"https://pubmed.ncbi.nlm.nih.gov/36190732","citation_count":64,"is_preprint":false},{"pmid":"29158695","id":"PMC_29158695","title":"PNPLA3 expression and its impact on the liver: current perspectives.","date":"2017","source":"Hepatic medicine : evidence and research","url":"https://pubmed.ncbi.nlm.nih.gov/29158695","citation_count":63,"is_preprint":false},{"pmid":"16505250","id":"PMC_16505250","title":"Variation in the adiponutrin gene influences its expression and associates with obesity.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/16505250","citation_count":62,"is_preprint":false},{"pmid":"31921875","id":"PMC_31921875","title":"PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease.","date":"2019","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31921875","citation_count":59,"is_preprint":false},{"pmid":"30912854","id":"PMC_30912854","title":"Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD.","date":"2019","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/30912854","citation_count":59,"is_preprint":false},{"pmid":"34288010","id":"PMC_34288010","title":"Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.","date":"2021","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/34288010","citation_count":57,"is_preprint":false},{"pmid":"23333103","id":"PMC_23333103","title":"PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease.","date":"2013","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/23333103","citation_count":57,"is_preprint":false},{"pmid":"25378656","id":"PMC_25378656","title":"The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25378656","citation_count":54,"is_preprint":false},{"pmid":"19542081","id":"PMC_19542081","title":"A common variant in the adiponutrin gene influences liver enzyme values.","date":"2009","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19542081","citation_count":52,"is_preprint":false},{"pmid":"32125756","id":"PMC_32125756","title":"PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings.","date":"2020","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/32125756","citation_count":52,"is_preprint":false},{"pmid":"16914601","id":"PMC_16914601","title":"Adiponutrin gene is regulated by insulin and glucose in human adipose tissue.","date":"2006","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16914601","citation_count":51,"is_preprint":false},{"pmid":"25641744","id":"PMC_25641744","title":"PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis.","date":"2015","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25641744","citation_count":51,"is_preprint":false},{"pmid":"34147109","id":"PMC_34147109","title":"Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis.","date":"2021","source":"BMC endocrine disorders","url":"https://pubmed.ncbi.nlm.nih.gov/34147109","citation_count":48,"is_preprint":false},{"pmid":"19729411","id":"PMC_19729411","title":"Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19729411","citation_count":47,"is_preprint":false},{"pmid":"39550037","id":"PMC_39550037","title":"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis.","date":"2024","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39550037","citation_count":46,"is_preprint":false},{"pmid":"12565853","id":"PMC_12565853","title":"Adiponutrin mRNA expression in white adipose tissue is rapidly induced by meal-feeding a high-sucrose diet.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12565853","citation_count":46,"is_preprint":false},{"pmid":"23155331","id":"PMC_23155331","title":"PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease.","date":"2012","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23155331","citation_count":46,"is_preprint":false},{"pmid":"39798707","id":"PMC_39798707","title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials.","date":"2025","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39798707","citation_count":40,"is_preprint":false},{"pmid":"25624712","id":"PMC_25624712","title":"PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.","date":"2015","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25624712","citation_count":40,"is_preprint":false},{"pmid":"31062641","id":"PMC_31062641","title":"PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease.","date":"2019","source":"Adipocyte","url":"https://pubmed.ncbi.nlm.nih.gov/31062641","citation_count":37,"is_preprint":false},{"pmid":"23278404","id":"PMC_23278404","title":"Impact of leptin receptor gene variants on risk of non-alcoholic fatty liver disease and its interaction with adiponutrin gene.","date":"2013","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/23278404","citation_count":36,"is_preprint":false},{"pmid":"31793207","id":"PMC_31793207","title":"PNPLA3 I148M mediates the regulatory effect of NF-kB on inflammation in PA-treated HepG2 cells.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31793207","citation_count":34,"is_preprint":false},{"pmid":"38365182","id":"PMC_38365182","title":"Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.","date":"2024","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/38365182","citation_count":31,"is_preprint":false},{"pmid":"38652636","id":"PMC_38652636","title":"PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.","date":"2024","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/38652636","citation_count":30,"is_preprint":false},{"pmid":"15068818","id":"PMC_15068818","title":"Macronutrient composition of the diet differentially affects leptin and adiponutrin mRNA expression in response to meal feeding.","date":"2004","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15068818","citation_count":30,"is_preprint":false},{"pmid":"31497741","id":"PMC_31497741","title":"PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells.","date":"2019","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/31497741","citation_count":30,"is_preprint":false},{"pmid":"30148144","id":"PMC_30148144","title":"PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease.","date":"2018","source":"World journal of clinical cases","url":"https://pubmed.ncbi.nlm.nih.gov/30148144","citation_count":29,"is_preprint":false},{"pmid":"32043752","id":"PMC_32043752","title":"Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH.","date":"2020","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/32043752","citation_count":28,"is_preprint":false},{"pmid":"21036152","id":"PMC_21036152","title":"Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21036152","citation_count":27,"is_preprint":false},{"pmid":"39412170","id":"PMC_39412170","title":"Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.","date":"2024","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/39412170","citation_count":27,"is_preprint":false},{"pmid":"17372308","id":"PMC_17372308","title":"Regulation of adiponutrin expression by feeding conditions in rats is altered in the obese state.","date":"2007","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/17372308","citation_count":27,"is_preprint":false},{"pmid":"25060692","id":"PMC_25060692","title":"Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells.","date":"2014","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/25060692","citation_count":26,"is_preprint":false},{"pmid":"35124887","id":"PMC_35124887","title":"ChREBP-driven DNL and PNPLA3 Expression Induced by Liquid Fructose are Essential in the Production of Fatty Liver and Hypertriglyceridemia in a High-Fat Diet-Fed Rat Model.","date":"2022","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/35124887","citation_count":26,"is_preprint":false},{"pmid":"36103835","id":"PMC_36103835","title":"Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36103835","citation_count":26,"is_preprint":false},{"pmid":"38657050","id":"PMC_38657050","title":"The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38657050","citation_count":24,"is_preprint":false},{"pmid":"19390624","id":"PMC_19390624","title":"Genetic variance in the adiponutrin gene family and childhood obesity.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19390624","citation_count":24,"is_preprint":false},{"pmid":"34249902","id":"PMC_34249902","title":"PNPLA3 and TLL-1 Polymorphisms as Potential Predictors of Disease Severity in Patients With COVID-19.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34249902","citation_count":24,"is_preprint":false},{"pmid":"35349726","id":"PMC_35349726","title":"PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features.","date":"2022","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/35349726","citation_count":24,"is_preprint":false},{"pmid":"26151055","id":"PMC_26151055","title":"PNPLA3 genetic variation in alcoholic steatosis and liver disease progression.","date":"2015","source":"Hepatobiliary surgery and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/26151055","citation_count":23,"is_preprint":false},{"pmid":"32386450","id":"PMC_32386450","title":"The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue.","date":"2020","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/32386450","citation_count":23,"is_preprint":false},{"pmid":"33531537","id":"PMC_33531537","title":"Greater liver PNPLA3 protein abundance in vivo and in vitro supports lower triglyceride accumulation in dairy cows.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33531537","citation_count":23,"is_preprint":false},{"pmid":"39882540","id":"PMC_39882540","title":"Global Epidemiology and Implications of PNPLA3 I148M Variant in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis.","date":"2024","source":"Journal of clinical and experimental hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39882540","citation_count":23,"is_preprint":false},{"pmid":"32093693","id":"PMC_32093693","title":"Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.","date":"2020","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/32093693","citation_count":22,"is_preprint":false},{"pmid":"21556044","id":"PMC_21556044","title":"Diet-induced obesity affects expression of adiponutrin/PNPLA3 and adipose triglyceride lipase, two members of the same family.","date":"2011","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/21556044","citation_count":21,"is_preprint":false},{"pmid":"32220085","id":"PMC_32220085","title":"PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States.","date":"2020","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/32220085","citation_count":21,"is_preprint":false},{"pmid":"32360822","id":"PMC_32360822","title":"PNPLA3 Gene Polymorphism and Liver- and Extrahepatic Cancer-Related Mortality in the United States.","date":"2020","source":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","url":"https://pubmed.ncbi.nlm.nih.gov/32360822","citation_count":21,"is_preprint":false},{"pmid":"30852978","id":"PMC_30852978","title":"Correlation between PNPLA3 rs738409 polymorphism and hepatocellular carcinoma: a meta-analysis of 10,330 subjects.","date":"2019","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/30852978","citation_count":21,"is_preprint":false},{"pmid":"36719059","id":"PMC_36719059","title":"PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.","date":"2023","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/36719059","citation_count":20,"is_preprint":false},{"pmid":"33218077","id":"PMC_33218077","title":"PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33218077","citation_count":20,"is_preprint":false},{"pmid":"38145725","id":"PMC_38145725","title":"Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD.","date":"2023","source":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","url":"https://pubmed.ncbi.nlm.nih.gov/38145725","citation_count":19,"is_preprint":false},{"pmid":"31054977","id":"PMC_31054977","title":"Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.","date":"2019","source":"Annals of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/31054977","citation_count":19,"is_preprint":false},{"pmid":"39054606","id":"PMC_39054606","title":"TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD.","date":"2024","source":"Clinical and molecular hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39054606","citation_count":18,"is_preprint":false},{"pmid":"37298640","id":"PMC_37298640","title":"PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37298640","citation_count":18,"is_preprint":false},{"pmid":"35884822","id":"PMC_35884822","title":"KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35884822","citation_count":18,"is_preprint":false},{"pmid":"24269995","id":"PMC_24269995","title":"The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients.","date":"2013","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24269995","citation_count":17,"is_preprint":false},{"pmid":"30403964","id":"PMC_30403964","title":"Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30403964","citation_count":17,"is_preprint":false},{"pmid":"28338112","id":"PMC_28338112","title":"PNPLA3 and RNF7 Gene Variants are Associated with the Risk of Developing Liver Fibrosis and Cirrhosis in an Eastern European Population.","date":"2017","source":"Journal of gastrointestinal and liver diseases : JGLD","url":"https://pubmed.ncbi.nlm.nih.gov/28338112","citation_count":17,"is_preprint":false},{"pmid":"39605307","id":"PMC_39605307","title":"Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.","date":"2024","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/39605307","citation_count":16,"is_preprint":false},{"pmid":"36615809","id":"PMC_36615809","title":"Interaction between the PNPLA3 Gene and Nutritional Factors on NAFLD Development: The Korean Genome and Epidemiology Study.","date":"2022","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/36615809","citation_count":16,"is_preprint":false},{"pmid":"19619606","id":"PMC_19619606","title":"Tri-iodothyronine upregulates adiponutrin mRNA expression in rat and human adipocytes.","date":"2009","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19619606","citation_count":15,"is_preprint":false},{"pmid":"39559944","id":"PMC_39559944","title":"PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.","date":"2024","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/39559944","citation_count":15,"is_preprint":false},{"pmid":"38294943","id":"PMC_38294943","title":"The ubiquitin E3 ligase BFAR promotes degradation of PNPLA3.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38294943","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":59441,"output_tokens":7916,"usd":0.148532,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17353,"output_tokens":7085,"usd":0.131945,"stage2_stop_reason":"end_turn"},"total_usd":0.280477,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Adiponutrin (PNPLA3) is a transmembrane protein that strictly localizes to membranes and is absent from the cytosol, as shown by Western blot and confocal imaging of epitope-tagged protein in 3T3-L1 adipocytes and COS cells. Its expression is exclusively in the adipose lineage and is tightly regulated by nutritional state (downregulated by fasting, dramatically induced by refeeding a high-carbohydrate diet).\",\n      \"method\": \"Western blot; confocal immunofluorescence imaging of epitope-tagged protein; mRNA differential display; Northern blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with epitope-tagged protein in two cell types, nutritional regulation confirmed in vivo, single lab\",\n      \"pmids\": [\"11431482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Recombinant adiponutrin (PNPLA3) displays lipase activity in vitro that is dependent on the presence of the active-site serine; however, unlike ATGL/Desnutrin, overexpression of adiponutrin does not decrease intracellular triglyceride levels in cells, indicating it does not contribute to net lipolysis.\",\n      \"method\": \"In vitro lipase assay with recombinant proteins; active-site serine mutation; cell-based overexpression with intracellular triglyceride quantification\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro activity assay with mutagenesis and cell-based functional assay, single lab\",\n      \"pmids\": [\"16150821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"siRNA-mediated knockdown of adiponutrin (PNPLA3) in 3T3-L1 adipocytes had no effect on glycerol or NEFA release, indicating adiponutrin does not contribute to net adipocyte lipolysis. Adiponutrin is oppositely regulated by insulin compared to ATGL (insulin increases adiponutrin and decreases ATGL expression).\",\n      \"method\": \"siRNA knockdown; lipolysis assay (glycerol and NEFA measurement); insulin dose-response in 3T3-L1 adipocytes; in vivo streptozotocin diabetic mouse model\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean siRNA KD with specific readout, supported by in vivo regulation data, single lab\",\n      \"pmids\": [\"16380488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Purified recombinant human PNPLA3 hydrolyzes triacylglycerol, diacylglycerol, and monoacylglycerol with preference for oleic acid as acyl moiety, and also catalyzes oleoyl-CoA thioesterase activity. The I148M substitution markedly decreases Vmax for glycerolipid substrates (loss of function) but has only modest effect on Km. PNPLA3 shows little to no hydrolytic activity against phospholipids, cholesteryl ester, or retinyl esters (by this assay), and neither WT nor I148M catalyzes de novo TAG synthesis.\",\n      \"method\": \"Purified recombinant protein; radiometric in vitro enzymatic assay; site-directed mutagenesis (catalytic serine; I148M); substrate specificity profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro with purified protein, mutagenesis, comprehensive substrate panel, replicated by multiple subsequent studies\",\n      \"pmids\": [\"21878620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Germline knockout of Pnpla3 in mice does not cause fatty liver, elevated liver enzymes, or insulin resistance under normal chow, high-fat diet, high-sucrose diet, or in the ob/ob background, indicating loss of PNPLA3 function alone is insufficient to cause fatty liver in mice.\",\n      \"method\": \"Gene-targeted Pnpla3 knockout mouse; liver triglyceride measurement; plasma AST/ALT; glucose/insulin tolerance tests; multiple dietary challenges\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse with multiple dietary challenges and metabolic phenotyping, independently replicated (PMID 21068004)\",\n      \"pmids\": [\"20648554\", \"21068004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Purified recombinant PNPLA3 (expressed in Pichia pastoris) shows predominant triglyceride lipase activity and mild lysophosphatidic acid acyltransferase (LPAAT) activity; the I148M mutation results in loss of function of both activities.\",\n      \"method\": \"Pichia pastoris expression system; Ni-affinity protein purification; in vitro enzymatic assay with radiolabeled substrates; I148M mutant comparison\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro with purified protein from independent expression system, replicates and extends PMID 21878620\",\n      \"pmids\": [\"24369119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PNPLA3 localizes to lipid droplets (LDs) via a process requiring an intact Brummer box domain. The NAFLD-linked I148M isoform leads to larger LDs upon overexpression, whereas decreased PNPLA3 levels produce smaller LDs. Co-expression of PNPLA3 with ABHD5/CGI-58 induces LD size reduction.\",\n      \"method\": \"Subcellular fractionation; immunofluorescence; live-cell imaging; overexpression and siRNA knockdown in fibroblast-like cells supplemented with lipids; domain deletion constructs\",\n      \"journal\": \"Biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization with domain mutants and functional readout (LD size), single lab\",\n      \"pmids\": [\"23398201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Purified wild-type PNPLA3 hydrolyzes retinyl palmitate into retinol and palmitic acid in human hepatic stellate cells (HSCs). The I148M variant markedly reduces this retinyl-palmitate lipase activity. PNPLA3 is highly expressed in HSCs, its expression is regulated by retinol availability and insulin, and increased PNPLA3 expression reduces lipid droplet content and promotes extracellular retinol release.\",\n      \"method\": \"Purified recombinant protein enzymatic assay; primary human HSC culture; siRNA knockdown; overexpression; retinol measurement; PNPLA3 genotype correlation with circulating retinol-binding protein 4 in human cohort\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified protein, cell-based functional validation in primary human HSCs, and human cohort correlation, multiple orthogonal methods\",\n      \"pmids\": [\"24670599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PNPLA3 mediates fatty acid-selective remodeling of triacylglycerols in hepatocytes. WT PNPLA3 accelerates turnover of oleic acid-labeled TAGs, while I148M impairs this activity and preferentially accumulates on lipid droplets compared to WT (which distributes more to ER/cytosol), consistent with impaired TAG remodeling causing lipid accumulation.\",\n      \"method\": \"13C-glycerol isotope labeling; D17-oleic acid pulse-chase; lipidomics; principal component analysis; subcellular fractionation; overexpression of WT and I148M in HuH7 cells\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal isotope labeling methods with subcellular localization, single lab\",\n      \"pmids\": [\"24511104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In human hepatic stellate cells (LX-2), stable overexpression of WT PNPLA3 (but not I148M mutant) reduces secretion of MMP2, TIMP1, and TIMP2, and this effect is mediated through retinoid metabolism. TGF-β upregulates PNPLA3 expression in HSCs and is involved in TGF-β-induced lipid droplet reduction. Retinol release from primary human HSCs is lower in cells with I148M compared to WT.\",\n      \"method\": \"Stable lentiviral overexpression in LX-2 cells; primary human HSC culture; ELISA for MMP2/TIMP1/TIMP2; retinol measurement; siRNA knockdown; TGF-β treatment\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean overexpression with functional protein secretion readout and retinol assay, single lab\",\n      \"pmids\": [\"27742777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PNPLA3(I148M) and the catalytically dead S47A mutant accumulate on hepatic lipid droplets when expressed in sucrose-fed mice and cause TG accumulation. Expression of a ubiquitylation-resistant form of PNPLA3 (which accumulates on LDs without loss of enzymatic activity) also causes fatty liver, demonstrating that LD accumulation of PNPLA3 itself—not loss of enzymatic activity—causes steatosis. Knockdown of PNPLA3 by shRNA or PROTAC-mediated degradation reduces liver TG in PNPLA3(148M)-overexpressing mice.\",\n      \"method\": \"AAV/adenoviral overexpression in mice; ubiquitylation-resistant PNPLA3 construct; shRNA knockdown; PROTAC degradation; liver TG measurement; LD immunostaining\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic constructs and orthogonal interventions (shRNA, PROTAC, engineered ubiquitylation-resistant variant) all pointing to the same conclusion in vivo\",\n      \"pmids\": [\"31019090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PNPLA3 (WT and I148M) interacts directly with CGI-58 (ABHD5), the cofactor of ATGL, as shown by co-immunoprecipitation and in vitro pulldown with purified proteins. PNPLA3 requires CGI-58 for localization to hepatic LDs, and PNPLA3(148M)-induced steatosis requires CGI-58 presence. Co-expression of PNPLA3 with CGI-58 depletes LDs, consistent with PNPLA3 inhibiting ATGL by sequestering CGI-58.\",\n      \"method\": \"Co-immunoprecipitation in mouse liver and cultured cells; in vitro pulldown with purified proteins; liver-specific Cgi-58 KO mice; overexpression in HuH-7 cells; liver TG measurement\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal Co-IP, in vitro pulldown with purified proteins, genetic epistasis in Cgi-58 KO mice, multiple orthogonal methods\",\n      \"pmids\": [\"30802989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In homozygous PNPLA3-I148M humans, VLDL-triglycerides are depleted of polyunsaturated fatty acids (PUFAs) under fasting and postprandial conditions. In PNPLA3-148M and PNPLA3-KO human cells, PUFA incorporation into TGs is increased at the expense of phosphatidylcholines, and PUFA-containing DAGs accumulate under lipolytic conditions compared to 148I cells. This establishes I148M as a loss-of-function allele that impairs hydrolysis/transacylation of PUFAs from DAGs to feed PC synthesis.\",\n      \"method\": \"Stable isotope tracer studies in humans; lipidomics in human cells with PNPLA3 genotype editing; VLDL-TG fatty acid composition in vivo; DAG accumulation assay\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — isotope tracing in vivo in humans plus isogenic cell models, multiple orthogonal methods, mechanistically definitive\",\n      \"pmids\": [\"31434800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ASO-mediated silencing of Pnpla3 in Pnpla3-I148M knock-in mice reduces liver steatosis, inflammation score, and fibrosis stage on a NASH-inducing diet (but not in WT littermates for fibrosis). This establishes that the steatosis and fibrosis phenotype associated with PNPLA3-I148M is dependent on expression of the mutant protein.\",\n      \"method\": \"GalNAc3-conjugated ASO liver-targeted silencing; Pnpla3-I148M knock-in mouse model; liver histology scoring (steatosis, inflammation, fibrosis); Mcp1 and Timp2 mRNA measurement\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic precision (knock-in model vs WT controls), liver-targeted silencing, multiple histological endpoints, genotype-specific effect\",\n      \"pmids\": [\"30772256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PNPLA3 I148M mediates NF-κB-driven inflammation in hepatocytes. NF-κB (p65/p50) binds a site in the PNPLA3 promoter to drive transcription; PNPLA3 silencing blocks NF-κB- or palmitic acid-induced TNF-α upregulation; mutant (but not WT) PNPLA3 overexpression activates the ER stress IRE-1α/JNK/c-Jun inflammatory pathway independently of NF-κB.\",\n      \"method\": \"Luciferase reporter assay; EMSA; ChIP-qPCR; siRNA knockdown; stable lentiviral overexpression; supershift analysis confirming p65/p50 complex\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (luciferase, EMSA, ChIP, siRNA), single lab\",\n      \"pmids\": [\"31793207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In primary I148M HSCs, LXRα protein is elevated but LXR target gene expression is reduced, LXR transcriptional activity is decreased, and cholesterol efflux is diminished while free cholesterol accumulates. The synthetic LXR agonist T0901317 restores LXR functionality and reduces pro-fibrogenic gene expression in I148M HSCs.\",\n      \"method\": \"Primary human HSC culture stratified by PNPLA3 genotype; LXR luciferase reporter assay; qRT-PCR of LXR targets; cholesterol assays; LXR agonist treatment\",\n      \"journal\": \"Hepatology communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genotype-stratified primary human HSCs with functional assays, single lab, no independent replication\",\n      \"pmids\": [\"31497741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PNPLA3 is highly abundant at the protein level in human adipose tissue (3-fold higher per tissue protein than liver). PNPLA3-I148M locally remodels adipose tissue TGs to become enriched in polyunsaturated species (PUFA-TGs increased in AT of variant carriers) without altering the rate of lipolysis or serum NEFA composition.\",\n      \"method\": \"PNPLA3 mRNA and protein quantification in paired liver and adipose tissue biopsies; AT lipidomics; [2H5]glycerol lipolysis tracer; genotype-stratified comparison\",\n      \"journal\": \"Liver international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein quantification in human tissue biopsies with lipidomics, single lab\",\n      \"pmids\": [\"32386450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The I148M variant drives enhanced NAFLD phenotype development through elevated IL-6/STAT3 and NF-κB activity in an isogenic hPSC-derived multicellular liver culture (hepatocytes, stellate cells, macrophages). Dampening IL-6/STAT3 activity alleviated I148M-mediated NAFLD phenotypes; boosting IL-6/STAT3 in WT cultures enhanced NAFLD, establishing a causal link.\",\n      \"method\": \"Isogenic hPSC-derived multicellular liver organoid system; CRISPR-Cas9 isogenic editing of rs738049; IL-6/STAT3 pathway inhibition/activation; transcriptomic analysis corroborated with human liver biopsy data\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isogenic CRISPR model with rescue experiment and pathway manipulation, single lab, corroborated by human transcriptomics\",\n      \"pmids\": [\"36049612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Estrogen receptor-α (ER-α) binds a functional enhancer element within the PNPLA3 locus to upregulate PNPLA3 expression. CRISPR-Cas9 deletion of this ER-α-binding site reduces PNPLA3-I148M upregulation and attenuates lipid droplet accumulation and fibrogenesis in 3D multilineage spheroids with stellate cells. Hepatic PNPLA3 expression is higher in women than men in obesity and correlates with estrogen levels in mice.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); luciferase reporter assay; CRISPR-Cas9 genome editing of ER-α binding site; 3D multilineage liver spheroids; hepatocyte and liver organoid treatment with ER-α agonists\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP, luciferase, CRISPR deletion, and functional validation in 3D organoids, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"37749332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Homozygous PNPLA3 I148M carriers have higher plasma β-hydroxybutyrate, lower hepatic de novo lipogenesis (DNL), and increased channeling of fatty acids toward ketogenesis associated with hepatic mitochondrial redox changes and decreased mitochondrial citrate synthase flux, demonstrating that the variant causes hepatic mitochondrial dysfunction.\",\n      \"method\": \"Stable isotope tracer studies (deuterium water for DNL; 13C acetate for ketogenesis); hepatic mitochondrial redox measurements; ketogenic diet challenge; genotype-stratified human study\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — state-of-the-art stable isotope techniques in humans under multiple physiological conditions, genotype-stratified, multiple orthogonal metabolic measurements\",\n      \"pmids\": [\"37909034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BFAR (bifunctional apoptosis regulator), a membrane-bound E3 ubiquitin ligase, promotes ubiquitylation and proteasomal/autophagic degradation of PNPLA3. BFAR and PNPLA3 co-immunoprecipitate when co-expressed; BFAR promotes PNPLA3 ubiquitylation in a reconstitution assay with purified proteins; BFAR knockdown increases PNPLA3 levels and Bfar KO mice show increased PNPLA3 protein on hepatic LDs without increased mRNA.\",\n      \"method\": \"siRNA screen of ubiquitin proteasome components; co-immunoprecipitation; in vitro ubiquitylation reconstitution assay with purified proteins; Bfar KO mouse; PNPLA3 protein/mRNA quantification\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro reconstitution of ubiquitylation, co-IP, and genetic validation in KO mouse, multiple orthogonal methods in single study\",\n      \"pmids\": [\"38294943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by accumulating on lipid droplets and sequestering ABHD5 (CGI-58) away from ATGL, thereby inhibiting ATGL-mediated TG hydrolysis. ABHD5 interacts preferentially with PNPLA3 over ATGL in hepatocytes. PNPLA3(WT and 148M) are both activated by ABHD5 in vitro. The steatotic effect requires ATGL expression and LD localization of PNPLA3. Overexpression of ABHD5 in Pnpla3(M/M) mice reverses hepatic steatosis.\",\n      \"method\": \"NanoBiT complementation assay for protein-protein interactions; immunocytochemistry; in vitro TG hydrolysis assay with purified recombinant proteins ± ABHD5; adenoviral/AAV overexpression in liver-specific Atgl-/- mice; ABHD5 overexpression in Pnpla3M/M mice; liver TG measurement\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro reconstitution, NanoBiT interaction assay, multiple genetic mouse models, epistasis experiment (ABHD5 rescue), mechanistically definitive\",\n      \"pmids\": [\"39550037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"At endogenous expression levels, PNPLA3 and PNPLA3-I148M are not ER-resident transmembrane proteins but are enriched in lipid droplet, Golgi, and endosomal fractions. PNPLA3-I148M induces morphological changes in the Golgi apparatus including increased lipid droplet-Golgi contact sites, observed both in isogenic hepatoma cells and primary human I148M-expressing hepatocytes.\",\n      \"method\": \"Isogenic CRISPR-engineered human hepatoma cell lines expressing PNPLA3 at endogenous levels; subcellular fractionation; immunofluorescence; electron microscopy; phosphoinositide binding assay with purified protein; proteomics; primary human hepatocytes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — endogenous expression isogenic system, multiple fractionation/imaging approaches, validated in primary patient hepatocytes, multiple orthogonal methods\",\n      \"pmids\": [\"38657050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TM6SF2 E167K variant increases physical interaction between TM6SF2 and PNPLA3, and impairs PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to phosphatidylcholine (PC), as shown in Tm6sf2-E167K knock-in mice on high-fat diet using lipidomics and TLC-based newly synthesized lipid measurement.\",\n      \"method\": \"Tm6sf2-E167K knock-in mouse; high-fat diet challenge; lipidomics; thin-layer chromatography for newly synthesized TG and PC; co-immunoprecipitation (TM6SF2–PNPLA3 interaction)\",\n      \"journal\": \"Clinical and molecular hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KI mouse model with lipidomics and Co-IP, single lab, mechanism of PNPLA3 transacylation activity implicated\",\n      \"pmids\": [\"39054606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The PNPLA3/adiponutrin promoter is regulated by glucose and insulin: glucose (25 mM) induces promoter activity 4.7-fold in HepG2 cells and 2-fold in CHO cells in a glucose metabolism-dependent manner; insulin has an additive effect in cells expressing the insulin receptor. USF2 transcription factor co-transfection further potentiates insulin-driven promoter activity.\",\n      \"method\": \"Luciferase reporter assay; promoter cloning; CHO-IR cell system; USF2 co-transfection; non-metabolizable glucose analog control\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — luciferase reporter with mutagenesis controls and non-metabolizable analog, single lab\",\n      \"pmids\": [\"21036152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In PNPLA3-I148M HSCs, expression and activation of the endogenous TGF-β inhibitor NR4A1 are decreased; NR4A1 regulation by TGF-β/cytosporone B was linked to Akt signaling in WT HSCs but Erk signaling in I148M HSCs. PNPLA3-I148M HSCs show impaired mitochondrial function (respiratory chain complex IV insufficiency), lower antioxidant capacity, increased ROS secretion, and increased TGF-β signaling.\",\n      \"method\": \"RNA sequencing of primary human HSCs and liver biopsies; 3D extracellular matrix scaffold culture; mitochondrial respirometry; ROS measurement; TGF-β and cytosporone B treatment; signaling pathway inhibitors\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomics plus 3D model validation with functional assays, single lab\",\n      \"pmids\": [\"38365182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PNPLA3-I148M in HSCs causes mitochondrial dysfunction through accumulation of free cholesterol (by decreasing ABCG1-mediated cholesterol efflux), leading to attenuated ATP production, decreased mitochondrial membrane potential, elevated ROS, and structural mitochondrial damage, thereby promoting HSC activation and fibrosis.\",\n      \"method\": \"Immunofluorescence; ELISA; real-time PCR; Western blot; electron microscopy; Seahorse XFe96 mitochondrial respirometry; cholesterol efflux assay in LX-2 cells overexpressing I148M vs WT\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays in cell line, single lab, mechanistic pathway identified\",\n      \"pmids\": [\"37298640\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PNPLA3 is a lipid droplet-associated serine hydrolase that, in hepatocytes, hydrolyzes triglycerides, diacylglycerols, and performs transacylation of polyunsaturated fatty acids from DAG to phosphatidylcholines, and in hepatic stellate cells also hydrolyzes retinyl palmitate to release retinol; the common I148M variant causes loss of enzymatic activity but, more critically, resists ubiquitin-mediated proteasomal/autophagic turnover (via the E3 ligase BFAR) and accumulates on lipid droplets where it sequesters the ATGL cofactor ABHD5 (CGI-58), thereby acting as a gain-of-function inhibitor of ATGL-mediated triglyceride hydrolysis to drive hepatic steatosis; in hepatic stellate cells the I148M variant additionally impairs retinol release, disrupts LXR-mediated cholesterol homeostasis, activates Yap/Hedgehog and TGF-β/NF-κB/IL-6-STAT3 pro-fibrogenic signaling, and causes mitochondrial dysfunction, collectively explaining its role in promoting the full spectrum of fatty liver disease from steatosis to fibrosis and hepatocellular carcinoma.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PNPLA3 is a lipid droplet-associated serine hydrolase that governs the remodeling of stored neutral lipids in hepatocytes and hepatic stellate cells, and its common I148M variant is a principal driver of fatty liver disease [#3, #21]. The purified enzyme hydrolyzes triacylglycerol, diacylglycerol, and monoacylglycerol with preference for oleate and additionally catalyzes acyltransferase reactions, activities that depend on its catalytic serine and are largely lost by the I148M substitution [#3, #5]. Mechanistically, PNPLA3 mediates fatty acid-selective remodeling of triglycerides, transferring polyunsaturated fatty acids from triglyceride/diacylglycerol pools toward phosphatidylcholine synthesis; I148M impairs this transacylation, depleting VLDL-triglycerides of PUFAs and causing accumulation of PUFA-containing diacylglycerols [#8, #12]. In hepatic stellate cells PNPLA3 instead hydrolyzes retinyl palmitate to release retinol, an activity also lost in the I148M protein [#7]. The decisive lesion in disease is not loss of catalysis but accumulation of the protein on lipid droplets: a ubiquitylation-resistant PNPLA3 that retains enzymatic activity still causes steatosis, establishing droplet accumulation itself as the steatotic driver [#10]. This accumulation reflects escape from turnover normally imposed by the membrane-bound E3 ubiquitin ligase BFAR, which ubiquitylates PNPLA3 to direct its proteasomal/autophagic degradation [#20]. Accumulated PNPLA3 acts as a gain-of-function inhibitor of ATGL-mediated lipolysis by binding and sequestering the ATGL cofactor ABHD5/CGI-58; CGI-58 is required for PNPLA3 localization to droplets and for I148M-driven steatosis, and ABHD5 overexpression reverses steatosis in I148M mice [#11, #21]. Beyond steatosis, the I148M variant drives the progression of liver disease through stellate-cell mitochondrial dysfunction, disrupted LXR-dependent cholesterol homeostasis, and activation of NF-\\u03baB and IL-6/STAT3 pro-inflammatory and pro-fibrogenic signaling [#15, #17, #26]. PNPLA3 expression is transcriptionally controlled by nutritional and hormonal cues, including glucose/insulin and estrogen receptor-\\u03b1 acting at a hepatic enhancer [#1, #24, #18].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established PNPLA3 as a nutritionally regulated, membrane-associated protein, framing it as a metabolic effector rather than a cytosolic enzyme.\",\n      \"evidence\": \"Western blot and confocal imaging of epitope-tagged protein in adipocyte/COS cells with nutritional regulation in vivo\",\n      \"pmids\": [\"11431482\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define enzymatic activity or substrate\", \"Adipose-restricted view later revised by hepatic and stellate-cell findings\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed PNPLA3 possesses intrinsic serine-dependent lipase activity yet does not drive net cellular lipolysis, distinguishing it from ATGL.\",\n      \"evidence\": \"In vitro lipase assay with recombinant protein, active-site serine mutant, and cell-based triglyceride quantification\",\n      \"pmids\": [\"16150821\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not resolve physiological substrate\", \"Disconnect between in vitro activity and cellular phenotype unexplained\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Confirmed PNPLA3 is dispensable for adipocyte lipolysis and is regulated oppositely to ATGL by insulin, sharpening its functional separation from canonical lipases.\",\n      \"evidence\": \"siRNA knockdown with glycerol/NEFA lipolysis readout and insulin dose-response in 3T3-L1 adipocytes\",\n      \"pmids\": [\"16380488\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No insight into hepatic role\", \"Substrate and direction of acyl chemistry unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated that loss of PNPLA3 function alone does not cause fatty liver, redirecting the field away from a simple loss-of-function model.\",\n      \"evidence\": \"Gene-targeted knockout mice across multiple dietary and ob/ob challenges with liver TG and metabolic phenotyping\",\n      \"pmids\": [\"20648554\", \"21068004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not explain how the human I148M variant causes disease\", \"Implied a gain-of-function or species-specific mechanism not yet defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined transcriptional control of PNPLA3 by glucose and insulin, linking its expression to nutritional state at the promoter level.\",\n      \"evidence\": \"Luciferase promoter reporter assays in HepG2/CHO-IR cells with USF2 co-transfection and non-metabolizable glucose control\",\n      \"pmids\": [\"21036152\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single transcription factor (USF2) tested\", \"Did not connect expression level to disease phenotype\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Reconstituted PNPLA3 as a glycerolipid hydrolase with oleate preference and showed I148M reduces Vmax, providing the first biochemical definition of the disease variant's enzymatic defect.\",\n      \"evidence\": \"Purified recombinant protein, radiometric assays, catalytic-serine and I148M mutagenesis, substrate panel\",\n      \"pmids\": [\"21878620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Loss of activity insufficient given KO mouse data\", \"No phospholipid or retinyl ester activity detected in this assay\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Independently confirmed triglyceride lipase activity (plus mild LPAAT activity) and the I148M loss-of-function, while localizing PNPLA3 to lipid droplets via the Brummer-box domain with droplet-size phenotypes.\",\n      \"evidence\": \"Pichia-expressed purified protein assays; subcellular fractionation, imaging, domain-deletion and ABHD5 co-expression in cells\",\n      \"pmids\": [\"24369119\", \"23398201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking droplet localization to enlargement unresolved\", \"Role of ABHD5 interaction not yet characterized\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed two tissue-specific catalytic roles: fatty acid-selective TAG remodeling in hepatocytes and retinyl-palmitate hydrolysis in stellate cells, both impaired by I148M.\",\n      \"evidence\": \"Isotope pulse-chase/lipidomics in HuH7 cells; purified-protein retinyl ester assay, primary human HSCs, and human cohort RBP4 correlation\",\n      \"pmids\": [\"24511104\", \"24670599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether remodeling defect alone causes steatosis\", \"Connection between hepatocyte and stellate-cell roles unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked PNPLA3 retinoid metabolism to fibrogenic output, showing WT but not I148M suppresses MMP2/TIMP secretion and that TGF-\\u03b2 induces PNPLA3 in stellate cells.\",\n      \"evidence\": \"Stable overexpression in LX-2 cells and primary HSCs with ELISA, retinol measurement, siRNA, and TGF-\\u03b2 treatment\",\n      \"pmids\": [\"27742777\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal chain from retinoid defect to fibrosis incomplete\", \"Single cell-line/primary-cell system\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Overturned the loss-of-function paradigm by showing droplet accumulation of PNPLA3 itself, independent of catalytic activity, causes steatosis, and that degrading PNPLA3 reverses it.\",\n      \"evidence\": \"AAV/adenoviral overexpression in mice, ubiquitylation-resistant and catalytically dead constructs, shRNA and PROTAC degradation, liver TG and LD imaging\",\n      \"pmids\": [\"31019090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular consequence of droplet accumulation not yet defined\", \"Identity of the turnover machinery unknown at this point\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified the gain-of-function mechanism: PNPLA3 binds CGI-58/ABHD5, requires it for droplet localization, and sequesters it from ATGL to inhibit lipolysis.\",\n      \"evidence\": \"Reciprocal Co-IP, in vitro pulldown with purified proteins, liver-specific Cgi-58 KO epistasis, and HuH-7 overexpression\",\n      \"pmids\": [\"30802989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and preferential binding versus ATGL not yet quantified\", \"How accumulation is achieved physiologically unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Pinpointed the in vivo human metabolic defect of I148M as impaired transfer of PUFAs from DAG/TG toward phosphatidylcholine, depleting VLDL-TG of PUFAs.\",\n      \"evidence\": \"Stable isotope tracers in homozygous I148M humans plus isogenic genotype-edited human cells with lipidomics\",\n      \"pmids\": [\"31434800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship between transacylation defect and droplet accumulation not integrated\", \"Tissue-specific contribution of liver vs adipose unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated genotype-dependent reversibility, with ASO silencing of mutant PNPLA3 reducing steatosis, inflammation, and fibrosis in I148M knock-in mice.\",\n      \"evidence\": \"GalNAc3-ASO liver-targeted silencing in Pnpla3-I148M knock-in mice with histological scoring\",\n      \"pmids\": [\"30772256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fibrosis effect not seen in WT controls\", \"Downstream signaling mediators not defined here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected PNPLA3-I148M to hepatocyte inflammation via NF-\\u03baB (which also drives PNPLA3 transcription) and an ER-stress IRE-1\\u03b1/JNK/c-Jun axis.\",\n      \"evidence\": \"Luciferase, EMSA/supershift, ChIP-qPCR, siRNA, and stable overexpression in hepatocyte models\",\n      \"pmids\": [\"31793207\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Causal contribution to in vivo inflammation not isolated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed I148M disrupts LXR-dependent cholesterol homeostasis in stellate cells and that an LXR agonist restores function and reduces fibrogenic gene expression.\",\n      \"evidence\": \"Genotype-stratified primary human HSCs with LXR luciferase reporter, target qPCR, cholesterol assays, and T0901317 treatment\",\n      \"pmids\": [\"31497741\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No independent replication\", \"Mechanistic link from lipase defect to LXR dysfunction not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Quantified PNPLA3 as highly abundant in human adipose tissue and showed I148M remodels adipose TGs toward PUFA enrichment without altering lipolysis.\",\n      \"evidence\": \"Paired liver/adipose protein quantification, AT lipidomics, and glycerol tracer in genotype-stratified humans\",\n      \"pmids\": [\"32386450\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of adipose remodeling for systemic disease unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined stellate-cell mitochondrial dysfunction as a fibrogenic consequence of I148M, driven by free-cholesterol accumulation and altered TGF-\\u03b2/NR4A1 signaling with elevated ROS.\",\n      \"evidence\": \"RNA-seq, 3D ECM and LX-2 culture, Seahorse respirometry, cholesterol efflux assays, signaling inhibitors\",\n      \"pmids\": [\"38365182\", \"37298640\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab cell models\", \"Direct link from enzyme defect to mitochondrial damage not fully reconstituted\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established IL-6/STAT3 as a causal pro-NAFLD pathway downstream of I148M using an isogenic multicellular human liver system with bidirectional manipulation.\",\n      \"evidence\": \"hPSC-derived multicellular liver organoids, CRISPR isogenic rs738049 editing, IL-6/STAT3 inhibition and activation, human transcriptomic corroboration\",\n      \"pmids\": [\"36049612\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single model system\", \"Upstream trigger connecting PNPLA3 to IL-6/STAT3 not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified estrogen receptor-\\u03b1 binding at a hepatic enhancer as a sex-dependent transcriptional driver of PNPLA3, providing a mechanism for sex differences in expression and fibrogenesis.\",\n      \"evidence\": \"ChIP, luciferase, CRISPR deletion of the ER-\\u03b1 site, and 3D multilineage spheroid functional validation\",\n      \"pmids\": [\"37749332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution to clinical sex differences not established\", \"Interaction with nutritional regulators not integrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated I148M causes hepatic mitochondrial dysfunction in humans, shifting fatty acids toward ketogenesis and reducing de novo lipogenesis and citrate synthase flux.\",\n      \"evidence\": \"Deuterium water and 13C-acetate tracers with mitochondrial redox measurements in genotype-stratified humans under ketogenic challenge\",\n      \"pmids\": [\"37909034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal link from droplet accumulation to mitochondrial change not mechanistically traced\", \"Hepatocyte vs stellate-cell contributions not separated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified BFAR as the E3 ligase that ubiquitylates PNPLA3 for degradation, explaining how mutant protein evades turnover to accumulate on droplets.\",\n      \"evidence\": \"Ubiquitin-proteasome siRNA screen, Co-IP, in vitro ubiquitylation reconstitution with purified proteins, and Bfar KO mice\",\n      \"pmids\": [\"38294943\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether I148M specifically resists BFAR-mediated ubiquitylation not fully quantified\", \"Relative roles of proteasomal vs autophagic disposal unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided the definitive gain-of-function model: PNPLA3 preferentially binds ABHD5 over ATGL, requires ATGL and droplet localization for steatosis, and ABHD5 overexpression reverses the phenotype.\",\n      \"evidence\": \"NanoBiT interaction assays, in vitro TG hydrolysis with purified proteins \\u00b1 ABHD5, liver-specific Atgl-/- mice, and ABHD5 rescue in Pnpla3 M/M mice\",\n      \"pmids\": [\"39550037\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ABHD5 preference unresolved\", \"Integration with transacylation defect mechanism not fully reconciled\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revised the subcellular localization model, showing endogenous PNPLA3 is enriched in lipid droplet, Golgi, and endosomal fractions rather than the ER, and that I148M alters Golgi morphology and LD-Golgi contacts.\",\n      \"evidence\": \"Isogenic endogenous-expression hepatoma lines, fractionation, immunofluorescence, EM, phosphoinositide binding, proteomics, and primary patient hepatocytes\",\n      \"pmids\": [\"38657050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of Golgi/endosomal pools unclear\", \"Significance of LD-Golgi contact sites for disease undefined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked PNPLA3 to TM6SF2 genetically, showing the TM6SF2-E167K variant enhances TM6SF2-PNPLA3 interaction and impairs PNPLA3-mediated PUFA transfer from TG to PC.\",\n      \"evidence\": \"Tm6sf2-E167K knock-in mice on high-fat diet, lipidomics, TLC of newly synthesized lipids, and Co-IP\",\n      \"pmids\": [\"39054606\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Whether TM6SF2 modulates PNPLA3 in humans not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the transacylation/PUFA-remodeling defect, droplet accumulation with ABHD5 sequestration, and downstream mitochondrial and pro-fibrogenic signaling are causally integrated into a single quantitative mechanism remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of PNPLA3 or PNPLA3-ABHD5 complex in the corpus\", \"Causal order linking droplet accumulation to mitochondrial and signaling phenotypes not established\", \"Therapeutic degradation strategies not validated clinically\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 5, 7]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [5, 12, 23]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [11, 21]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [6, 8, 10, 22]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 8, 12, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 13, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 17, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ABHD5\", \"ATGL\", \"BFAR\", \"TM6SF2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":9,"faith_total":9,"faith_pct":100.0}}